It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Developmental thymic waves of innate-like and adaptive-like γδ T cells have been described, but the current understanding of γδ T cell development is mainly limited to mouse models. Here, we combine single cell (sc) RNA gene expression and sc γδ T cell receptor (TCR) sequencing on fetal and pediatric γδ thymocytes in order to understand the ontogeny of human γδ T cells. Mature fetal γδ thymocytes (both the Vγ9Vδ2 and nonVγ9Vδ2 subsets) are committed to either a type 1, a type 3 or a type 2-like effector fate displaying a wave-like pattern depending on gestation age, and are enriched for public CDR3 features upon maturation. Strikingly, these effector modules express different CDR3 sequences and follow distinct developmental trajectories. In contrast, the pediatric thymus generates only a small effector subset that is highly biased towards Vγ9Vδ2 TCR usage and shows a mixed type 1/type 3 effector profile. Thus, our combined dataset of gene expression and detailed TCR information at the single-cell level identifies distinct functional thymic programming of γδ T cell immunity in human.
Knowledge about the ontogeny of T cells in the thymus relies heavily on mouse studies because of difficulty to obtain human material. Here the authors perform a single cell analysis of thymocytes from human fetal and paediatric thymic samples to characterise the development of human γδ T cells in the thymus.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Université Libre de Bruxelles (ULB), Department of Pharmacotherapy and Pharmaceutics, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746); Université Libre de Bruxelles (ULB), Institute for Medical Immunology, Gosselies, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746); Université Libre de Bruxelles (ULB), ULB Center for Research in Immunology (U-CRI), Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746)
2 Université Libre de Bruxelles (ULB), Institute for Medical Immunology, Gosselies, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746); Université Libre de Bruxelles (ULB), ULB Center for Research in Immunology (U-CRI), Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746)
3 Singapore Immunology Network (SIgN), A*STAR, Singapore, Singapore (GRID:grid.430276.4) (ISNI:0000 0004 0387 2429); Telethon Kids Institute, University of Western Australia, Perth, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910)
4 KK Women’s and Children’s Hospital, Department of Reproductive Medicine, Singapore, Singapore (GRID:grid.414963.d) (ISNI:0000 0000 8958 3388); National University of Singapore, Experimental Fetal Medicine Group, Yong Loo Lin School of Medicine, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431); Duke-NUS Medical School, Academic Clinical Program in Obstetrics and Gynaecology, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924)
5 BRIGHTcore ULB-VUB, Université Libre de Bruxelles (ULB), Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746)
6 Singapore Immunology Network (SIgN), A*STAR, Singapore, Singapore (GRID:grid.430276.4) (ISNI:0000 0004 0387 2429)
7 Ghent University, Department of Diagnostic Sciences, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798)
8 Université Libre de Bruxelles (ULB), Department of Pharmacotherapy and Pharmaceutics, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746); Université Libre de Bruxelles (ULB), Institute for Medical Immunology, Gosselies, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746); Université Libre de Bruxelles (ULB), ULB Center for Research in Immunology (U-CRI), Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746); Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Wavre, Belgium (GRID:grid.509491.0)